BIIB061 / Biogen - LARVOL DELTA

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Biogen | N=300 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • CNS Disorders • Multiple Sclerosis

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) (clinicaltrials.gov) - P2; N=300; Not yet recruiting; Sponsor: Biogen; Trial completion date: Jul 2023 ➔ Sep 2024; Trial primary completion date: Jul 2023 ➔ Sep 2024

Clinical • Trial completion date • Trial primary completion date • CNS Disorders • Multiple Sclerosis

"Remyielination!!!?? #BIIB061 #opicinumab @biogen #elezanumab @AbbVieUS #CNMAu8 @CleneNano #Inception5 @Roche @genentech" (@ALFONFX)

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) (clinicaltrials.gov) - P2; N=300; Not yet recruiting; Sponsor: Biogen; Trial completion date: Oct 2022 ➔ Jul 2023; Initiation date: Jun 2020 ➔ Sep 2020; Trial primary completion date: Oct 2022 ➔ Jul 2023

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • CNS Disorders • Multiple Sclerosis

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) in Relapsing Multiple Sclerosis (RMS) (clinicaltrials.gov) - P2; N=300; Not yet recruiting; Sponsor: Biogen; Initiation date: Dec 2019 ➔ Jun 2020

Clinical • Trial initiation date

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) in Relapsing Multiple Sclerosis (RMS) (clinicaltrials.gov) - P2; N=300; Not yet recruiting; Sponsor: Biogen; Trial primary completion date: May 2022 ➔ Oct 2022

Clinical • Trial primary completion date

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) in Relapsing Multiple Sclerosis (RMS) (clinicaltrials.gov) - P2; N=300; Not yet recruiting; Sponsor: Biogen

Clinical • New P2 trial